The project management is responsible for the content of the information provided.
This project, funded by Gebert Rüf Stiftung, is supported by the following project partners: University of Bern, NCCR TransCure, Innosuisse, BaseLaunch, Venture Kick, Horizon2020 programme (SME Instrument)
Données de projet
Numéro du projet: GRS-040/19
Subside accordé: CHF 150'000
Durée: 08.2019 - 10.2020
InnoBooster, seit 2018
Direction du projet
Inst. of Biochemistry & Molecular Medicine
3012 Bern (Schweiz)
- firstname.lastname@example.org. ch
Neuropsychiatric disorders are still one of the highest unmet medical needs in human medicine. The major problem is lack of innovation and urgent need for of safe and effective drugs for these disorders.
Synendos develops an innovative approach based upon first-in-class inhibitors. The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds followed by a thorough medicinal chemistry programme. In total, 800 purchasable and newly synthetized compounds were tested leading to the selection of the preclinical drug candidate at the end of 2018.
Our mission at Synendos is to advance the development of this new class of inhibitors and provide a more safe and effective therapy for unmet needs in neuropsychiatric disorders.
Quelles sont les particularités de ce projet?
At Synendos, we develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders. Our first-in-class inhibitors enables restoration of natural functioning of the brain through the modulation a new drug target (not yet published), which was recently identified at the University of Bern after 8 years of basic research.
Unlike current drugs, our inhibitors offer a potential superior safety profile for short and long term use and an improved therapeutic control of the symptoms associated to neuropsychiatric disorders. These effects can be achieved thanks to an innovative self-limiting mechanism of action that mildly but effectively restore the natural functioning of different neuronal circuits. Thanks to this pro-homeostatic effect on neurotransmission and neuronal plasticity, our inhibitors have the potential to become the first effective treatment for unmet needs in neuropsychiatric disorders with enormous benefit for patients, healthcare providers, communities and society.
We recently identified our preclinical drug candidate with two potential follow up/back up compounds after a thorough medicinal chemistry programme. Several activities are ongoing to finalize non-regulatory preclinical tests, which are followed by regulatory preclinical safety study. Synendos aims to enter into human trials as soon as the preclinical development will be completed.
The identification of the new drug target enables Synendos to optimize a drug discovery platform to identify new generation inhibitors and expand its pipeline.
Over the past 6 years at the University of Bern, the project has been supported by a number of agencies (NCCR-TransCure, Innosuisse, foundations). In 2019 in addition to Gebert Rüf Stiftung, Synendos has received financial support from BaseLaunch, Venture Kick, Horizon2020 programme (European Union). Synendos is in advanced stage of discussion with several investors to secure financing for preclinical and early clinical development activities.
Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J. The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. Front Mol Neurosci. 2018 May 28; 11:180.
Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Dalghi Gens M, Lutz B, Schiöth HB, Soeberdt M, Abels C, Charles RP, Altmann KH, Gertsch J. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A. 2017 Jun 20;114(25): E5006-E5015.
Revue de presse
Personnes participant au projet
Dernière mise à jour de cette présentation du projet 12.11.2020